Transcatheter Procedure Performed Using the Capstan Compass™ Robotic System
CINCINNATI (November 17, 2026) – Capstan Medical, a developer of robotic-enabled, minimally invasive solutions to address heart valve disease, announced the successful completion of its first robotic-assisted transcatheter mitral valve replacement (TMVR) procedure in the United States. The procedure was performed November 9 at The Christ Hospital Health Network by a team led by Santiago Garcia, MD, Director of the Structural Heart Program. The procedure was conducted as part of a U.S. Food and Drug Administration (FDA)-authorized early feasibility study.
"This first U.S. procedure represents another significant step forward in the treatment of structural heart disease," said Dr. Garcia. "The robotic platform is designed for catheter stability and control, with a goal to achieve precise positioning of the mitral valve implant. This technology could have the potential to fundamentally change what's possible for patients who cannot undergo conventional heart surgery.”
Mitral regurgitation occurs when the mitral valve does not close properly, allowing blood to flow backward through the heart. Many patients are too high-risk for conventional surgery and the existing catheter-based treatments are not suitable for all patients.
Capstan's investigational TMVR technology combines a flexible, multi-axis catheter, robotic navigation and a novel valve implant. Designed to treat a greater number of mitral valve patients and overcome the challenges of navigating the heart's complex anatomy. The system gives physicians precise control over catheter movement, valve positioning and deployment during minimally invasive procedures.
In lieu of managing multiple knobs on a traditional catheter systems, the Capstan System enables physicians to perform the TMVR procedure via inputs from a handheld controller with precise control over catheter movement, valve positioning and deployment.
"For patients who cannot undergo conventional heart surgery, our goal is to make valve replacement a reproducible and lower-stress procedure," said Maggie Nixon, Chief Executive Officer of Capstan Medical. "This first U.S. case builds on our initial clinical experience and brings us another step closer to expanding treatment options to patients who need them most."
The milestone follows Capstan's pioneering first-in-human robotic-assisted mitral valve replacement procedures, completed in Chile and announced in March 2025. Dr. Garcia was also present in those procedures.
About The Christ Hospital Health Network
The Christ Hospital Health Network consists of an acute care hospital located in Mt. Auburn, a remote hospital location in Liberty Township, eight ambulatory outpatient centers and dozens of medical offices throughout the region. For 138 years, The Christ Hospital has provided compassionate care to those it serves. Made up of more than 1,300 physicians and more than 7,600 team members, our mission is to improve the health of our community by providing exceptional outcomes in an affordable way. The Network was recognized by U.S. News & World Report as the #3 hospital in Ohio and named to Newsweek’s World’s Best Hospitals list in 2026.
About Capstan Medical
Founded in 2020, Capstan Medical is creating a new standard for minimally invasive heart valve intervention. The company is developing a suite of next-generation heart valve implants and a first-of-its-kind catheter-based robotic delivery platform designed to expand treatment options for patients with structural heart disease. For more information, visit www.capstanmedical.com.
The Capstan Compass TMVR system is investigational and is not approved for commercial use in the United States.
###
